Genomic Health, Inc. (NASDAQ:GHDX) insider Kimberly J. Popovits sold 5,000 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $30.22, for a total transaction of $151,100.00. The transaction was disclosed in a filing with the SEC, which is available through this link.

Kimberly J. Popovits also recently made the following trade(s):

  • On Wednesday, July 5th, Kimberly J. Popovits sold 1,468 shares of Genomic Health stock. The shares were sold at an average price of $32.67, for a total transaction of $47,959.56.
  • On Wednesday, July 5th, Kimberly J. Popovits sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $32.59, for a total transaction of $162,950.00.
  • On Monday, June 5th, Kimberly J. Popovits sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $32.32, for a total transaction of $161,600.00.

Shares of Genomic Health, Inc. (NASDAQ GHDX) traded down 0.99% during trading on Thursday, reaching $30.02. 136,407 shares of the company traded hands. Genomic Health, Inc. has a 12-month low of $25.66 and a 12-month high of $33.97. The firm’s market capitalization is $1.04 billion. The company has a 50 day moving average price of $31.94 and a 200 day moving average price of $31.23.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.02. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The business had revenue of $85.50 million for the quarter, compared to the consensus estimate of $86.08 million. During the same period in the previous year, the firm earned ($0.18) earnings per share. The company’s revenue was up 4.3% compared to the same quarter last year. On average, equities analysts predict that Genomic Health, Inc. will post ($0.01) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/17/genomic-health-inc-ghdx-insider-kimberly-j-popovits-sells-5000-shares.html.

A number of large investors have recently bought and sold shares of GHDX. Dubuque Bank & Trust Co. acquired a new stake in Genomic Health during the first quarter worth $142,000. Legal & General Group Plc raised its stake in Genomic Health by 48.7% in the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock worth $196,000 after buying an additional 2,038 shares during the last quarter. SG Americas Securities LLC raised its stake in Genomic Health by 37.8% in the second quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock worth $199,000 after buying an additional 1,679 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Genomic Health during the first quarter worth $218,000. Finally, Stonebridge Capital Management Inc. acquired a new stake in Genomic Health during the first quarter worth $259,000. 88.54% of the stock is currently owned by hedge funds and other institutional investors.

GHDX has been the topic of several research analyst reports. Raymond James Financial, Inc. reissued a “market perform” rating on shares of Genomic Health in a research note on Wednesday, May 3rd. They noted that the move was a valuation call. Jefferies Group LLC increased their price target on shares of Genomic Health from $29.00 to $33.00 and gave the company a “hold” rating in a research note on Wednesday, May 10th. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Piper Jaffray Companies reissued a “hold” rating and set a $31.00 price target on shares of Genomic Health in a research note on Thursday, August 3rd. Finally, BidaskClub cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $32.00.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.